Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 2,100 of 2,219.
    «« First « Previous 2096  2097  2098  2099  2100  2101  2102  2103  2104  Next» Last»»
    EudraCT Number: 2016-003334-25 Sponsor Protocol Number: Uni-Koeln-2785 Start Date*: 2017-01-26
    Sponsor Name:University of Cologne
    Full Title: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
    Medical condition: Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002619-24 Sponsor Protocol Number: R668-ABPA-1923 Start Date*: 2020-09-08
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis
    Medical condition: Allergic bronchopulmonary aspergillosis (ABPA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10001707 Allergic bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) FR (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000441-41 Sponsor Protocol Number: NB-ND021(NM21-1480)-101 Start Date*: 2021-10-26
    Sponsor Name:Numab Therapeutics AG
    Full Title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003117-18 Sponsor Protocol Number: AMLSG21-13 Start Date*: 2014-07-14
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13
    Medical condition: Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003208-42 Sponsor Protocol Number: CA209-6GE Start Date*: 2022-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage...
    Medical condition: Resected Stage IIIA/B/C/D or Stage IV melanoma in an adjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) BE (Completed) PL (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003568-73 Sponsor Protocol Number: GECP06/01 Start Date*: 2008-05-07
    Sponsor Name:Grupo Espagnol de Cancer de Pulmon
    Full Title: Phase III, Multicenter, Open-label, Randomized Study of Erlotinib (Tarceva®) Treatment Versus Chemotherapy in Patients with Advanced Non-small-cell Carcinoma of the Lung Who Present Mutations in th...
    Medical condition: Non-squamous-cell, non-small-cell lung cancer in stage IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004409-17 Sponsor Protocol Number: M16-049 Start Date*: 2019-06-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis
    Medical condition: Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-003008-42 Sponsor Protocol Number: ZN-d5-003 Start Date*: 2021-12-22
    Sponsor Name:K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
    Full Title: A Single-Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
    Medical condition: Relapsed or Refractory Light-Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2022-003279-41 Sponsor Protocol Number: PSY-NIL-0013 Start Date*: 2023-03-31
    Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy
    Full Title: Investigating N-methyl-d-aspartate (NMDA) receptor alterations in major depressive disorder by brain PET
    Medical condition: Major Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001911-96 Sponsor Protocol Number: D9488C00001 Start Date*: 2021-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants wit...
    Medical condition: Chronic kidney disease (CKD) with hyperkalaemia or at risk of hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003698-24 Sponsor Protocol Number: 40411813EPY2001 Start Date*: 2021-06-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects with Focal Ons...
    Medical condition: Focal Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    21.1 10029205 - Nervous system disorders 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004467-50 Sponsor Protocol Number: SFN-3-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004436-21 Sponsor Protocol Number: WN42636 Start Date*: 2021-08-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTH...
    Medical condition: Generalized Myasthenia Gravis (gMG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) NL (Completed) FR (Completed) PL (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004303-12 Sponsor Protocol Number: SFN-1-2019 Start Date*: 2020-10-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and preserved kidney function on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-003266-21 Sponsor Protocol Number: PSY-NIL-0012 Start Date*: 2023-03-31
    Sponsor Name:Medical University of Vienna
    Full Title: Acute effects of ketamine on the glutamatergic NMDA receptor quantified by PET and the radioligand (R)-[11C]-Me-NB1
    Medical condition: Acute effects of ketamine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004447-80 Sponsor Protocol Number: SFN-2-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Type 2 diabetes with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002786-35 Sponsor Protocol Number: CUA1 Start Date*: 2020-06-25
    Sponsor Name:Charlotte Uggerhøj Andersen
    Full Title: Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis.
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001289-14 Sponsor Protocol Number: MIT-Do001-C301 Start Date*: 2020-02-05
    Sponsor Name:Estetra SRL
    Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf...
    Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    21.0 10047065 - Vascular disorders 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002469-41 Sponsor Protocol Number: EZH-202 Start Date*: 2016-04-18
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    Medical condition: Cohort 1: Rhabdoid tumors (malignant rhabdoid tumors, rhabdoid tumors of the kidney, atypical teratoid rhabdoid tumors, and selected tumors Cohort 2: Relapsed/refractory synovial sarcoma with SS18...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026667 Malignant peripheral nerve sheath tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002951-40 Sponsor Protocol Number: CVL-751-PD-003 Start Date*: 2020-07-29
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parki...
    Medical condition: Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) HU (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2096  2097  2098  2099  2100  2101  2102  2103  2104  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 03:57:15 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA